ATE297739T1 - Endothelin-antagonisten zur behandlung von herzversagen - Google Patents

Endothelin-antagonisten zur behandlung von herzversagen

Info

Publication number
ATE297739T1
ATE297739T1 AT97914955T AT97914955T ATE297739T1 AT E297739 T1 ATE297739 T1 AT E297739T1 AT 97914955 T AT97914955 T AT 97914955T AT 97914955 T AT97914955 T AT 97914955T AT E297739 T1 ATE297739 T1 AT E297739T1
Authority
AT
Austria
Prior art keywords
heart failure
treatment
endothelin antagonists
blooded animal
warm blooded
Prior art date
Application number
AT97914955T
Other languages
English (en)
Inventor
Joseph J Lynch Jr
You-Tang Shen
Original Assignee
Banyu Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Banyu Pharma Co Ltd filed Critical Banyu Pharma Co Ltd
Application granted granted Critical
Publication of ATE297739T1 publication Critical patent/ATE297739T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Materials For Photolithography (AREA)
  • Photosensitive Polymer And Photoresist Processing (AREA)
AT97914955T 1996-04-04 1997-03-19 Endothelin-antagonisten zur behandlung von herzversagen ATE297739T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US1488296P 1996-04-04 1996-04-04
PCT/US1997/003737 WO1997037665A1 (en) 1996-04-04 1997-03-19 Method of treating heart failure with endothelin antagonists

Publications (1)

Publication Number Publication Date
ATE297739T1 true ATE297739T1 (de) 2005-07-15

Family

ID=21768326

Family Applications (1)

Application Number Title Priority Date Filing Date
AT97914955T ATE297739T1 (de) 1996-04-04 1997-03-19 Endothelin-antagonisten zur behandlung von herzversagen

Country Status (25)

Country Link
US (3) US5834483A (de)
EP (1) EP0906108B1 (de)
JP (2) JP3345891B2 (de)
KR (1) KR20000005178A (de)
CN (1) CN1215335A (de)
AT (1) ATE297739T1 (de)
AU (1) AU723351B2 (de)
BG (1) BG102716A (de)
BR (1) BR9708525A (de)
CA (1) CA2249330C (de)
CZ (1) CZ296098A3 (de)
DE (1) DE69733557T2 (de)
EA (1) EA003587B1 (de)
EE (1) EE9800315A (de)
ES (1) ES2241047T3 (de)
HU (1) HUP9903893A3 (de)
IL (1) IL126175A (de)
IS (1) IS4847A (de)
NO (1) NO984564L (de)
NZ (1) NZ331789A (de)
PL (1) PL329077A1 (de)
SK (1) SK130098A3 (de)
TR (1) TR199801988T2 (de)
UA (1) UA50761C2 (de)
WO (1) WO1997037665A1 (de)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997037665A1 (en) 1996-04-04 1997-10-16 Banyu Pharmaceutical Co., Ltd. Method of treating heart failure with endothelin antagonists
AU711936B2 (en) * 1996-08-09 1999-10-28 Banyu Pharmaceutical Co., Ltd. Stereoselective deoxygenation reaction
EP1049691B1 (de) 1998-01-21 2004-02-18 Banyu Pharmaceutical Co., Ltd. Substituierte 5-(2,2difluor-1,3-benzodioxol-5-yl) cyclopentenopyridinderivate
US8168616B1 (en) 2000-11-17 2012-05-01 Novartis Ag Combination comprising a renin inhibitor and an angiotensin receptor inhibitor for hypertension
JPWO2004060885A1 (ja) * 2002-12-27 2006-05-11 株式会社カネカ 光学活性２−チオメチル−３−フェニルプロピオン酸誘導体およびその合成中間体の製造法
CA2545641A1 (en) 2003-11-17 2005-06-02 Novartis Ag Use of organic compounds
GB0327839D0 (en) 2003-12-01 2003-12-31 Novartis Ag Organic compounds
JP2007529459A (ja) 2004-03-17 2007-10-25 ノバルティス アクチエンゲゼルシャフト 治療に置けるレニン阻害剤の使用
JP4967136B2 (ja) 2005-06-24 2012-07-04 国立大学法人 東京医科歯科大学 薬剤溶出性ステント
WO2011116115A1 (en) 2010-03-16 2011-09-22 Novartis Ag Aliskiren composition comprising a medium chain fatty acid, their process of manufacturing

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4971959A (en) * 1987-04-14 1990-11-20 Warner-Lambert Company Trisubstituted phenyl analogs having activity for congestive heart failure
GB9007762D0 (en) * 1990-04-05 1990-06-06 Beecham Group Plc Novel compounds
US5565485A (en) * 1993-03-19 1996-10-15 Merck & Co., Inc. Biphenyl compounds useful or endothelin antagonists
ES2172535T3 (es) 1993-04-27 2002-10-01 Smithkline Beecham Corp Antagonistas de los receptores de la endotelina.
US5571813A (en) * 1993-06-10 1996-11-05 Beiersdorf-Lilly Gmbh Fused pyrimidine compounds and their use as pharmaceuticals
US5389620A (en) * 1993-08-18 1995-02-14 Banyu Pharmaceutical Co., Ltd. Endothelin antagonistic heteroaromatic ring-fused cyclopentene derivatives
AU675870B2 (en) * 1993-08-18 1997-02-20 Msd K.K. Endothelin antagonistic heteroaromatic ring-fused cyclopentene derivatives
US5658943A (en) * 1995-01-05 1997-08-19 Warner-Lambert Company Phenylalanine derivatives as endothelin antagonists
WO1997037665A1 (en) * 1996-04-04 1997-10-16 Banyu Pharmaceutical Co., Ltd. Method of treating heart failure with endothelin antagonists

Also Published As

Publication number Publication date
HUP9903893A2 (hu) 2001-04-28
EP0906108A4 (de) 2000-12-06
JP2002220337A (ja) 2002-08-09
DE69733557D1 (de) 2005-07-21
AU723351B2 (en) 2000-08-24
JP2000510824A (ja) 2000-08-22
US6380195B1 (en) 2002-04-30
EE9800315A (et) 1999-06-15
ES2241047T3 (es) 2005-10-16
US6087360A (en) 2000-07-11
AU2202597A (en) 1997-10-29
EP0906108B1 (de) 2005-06-15
CA2249330C (en) 2005-08-09
BG102716A (en) 1999-09-30
DE69733557T2 (de) 2005-11-03
CA2249330A1 (en) 1997-10-16
CN1215335A (zh) 1999-04-28
PL329077A1 (en) 1999-03-15
HUP9903893A3 (en) 2001-05-28
IL126175A (en) 2003-05-29
EA199800889A1 (ru) 1999-04-29
WO1997037665A1 (en) 1997-10-16
UA50761C2 (uk) 2002-11-15
NO984564L (no) 1998-12-04
NZ331789A (en) 2000-05-26
NO984564D0 (no) 1998-09-30
IL126175A0 (en) 1999-05-09
BR9708525A (pt) 1999-08-03
CZ296098A3 (cs) 1999-06-16
EA003587B1 (ru) 2003-06-26
US5834483A (en) 1998-11-10
IS4847A (is) 1998-09-15
TR199801988T2 (xx) 2000-08-21
SK130098A3 (en) 1999-05-07
EP0906108A1 (de) 1999-04-07
JP3345891B2 (ja) 2002-11-18
KR20000005178A (ko) 2000-01-25

Similar Documents

Publication Publication Date Title
ATE218854T1 (de) Behandlung von herzrythmusstörungen durch hemmung einer multifunktionalen calcium/calmodulin- abhängigen protein kinase
DE69925024D1 (de) Verwendung von eph-rezeptor-antagonisten und agonisten zur behandlung von vaskulären krankheiten
CY1109191T1 (el) Μια νεα χρηση της δεφεριπρονης
BG106118A (en) Method for the treatment of fibrosis using an antagonist of the integrin alpha-4 subunit
ATE422357T1 (de) Verwendung von allopurinol zur behandlung von bluthochdruck
ATE297739T1 (de) Endothelin-antagonisten zur behandlung von herzversagen
ATE453402T1 (de) Verwendung von serp-1 in kombination mit einem immunosuppressor zur behandlung von arthritis
DE69800859D1 (de) Verwendung von Moxonidin zur Behandlung neuropathischer Schmerzen
MX9701187A (es) Nuevas lactamas naftofusionadas n-substituidas.
PT1237562E (pt) Processo de preparacao de extractos de micania contendo micanolida e di-hidromicanolida e utilizacao no tratamento das doencas proliferativas
DE60026883D1 (de) Methoden und zusammensetzungen zur behandlung von schmerzen
ATE242641T1 (de) Behandlung von stressinduzierten hautkrankheiten unter verwendung von corticoliberin (crh)- antagonisten und inhibitoren der hautmastzell- degranulation
DE69818809D1 (de) Verfahren zur behandlung von narbengewebe
ATE293972T1 (de) Behandlung von chronischen schmerzen
DE69218200D1 (de) Behandlung von leberkrebs
ATE268170T1 (de) Verwendung von bernsteisäure oder deren salze zur behandlung von insulinresistenz
TR200000090T2 (tr) Serotonin'in seçici olarak yeniden yapıya alınma inhibitörleri (SSRI) kullanılarak kalp hastalıklarının tedavisi ve önlenmesi.
ATE236633T1 (de) Topische verwendung von loperamid zur behandlung mikrobieller infektionen
DE69734349D1 (de) Behandlung von knochenleiden mit adrenomedullin
DE69733321D1 (de) Olanzapine zur behandlung von drogenmissbrauch
ATE209042T1 (de) Verwendung des wachstumshormons in mitteln zur behandlung der insulinresistenz im herzen
DE69635282D1 (de) Behandlung der exzessiven aggressivität mit olanzapine
DE69732851D1 (de) Verwendung von dextrinsulfat zur behandlung von sehr vasculären tumoren
ATE312606T1 (de) Verwendung eines imidazolderivats zur behandlung oder verhütung von hypotension und schock

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties